ArticleBMC endocrine disorders2026
Joint association of body roundness index and HOMA-IR with risk of MASLD in Korean populations.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the global prevalence of obesity rises, the clinical focus is shifting from simple BMI to a systemic perspective that integrates body composition and metabolic health. This study evaluates the association between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and the combined influence of insulin resistance and obesity-related body shape indices.
methodsUtilizing the KoGES cohort (n = 3,196), participants were categorized into four groups based on the median values of HOMA-IR and the Body Roundness Index (BRI). MASLD was defined by an HSI score > 36, at least one metabolic component, and controlled alcohol consumption (< 30 g/day for men, < 20 g/day for women). Cox proportional hazard regression was conducted to assess the risk across groups, including interaction and subgroup analyses to determine the independence of these markers.
resultsBoth HOMA-IR and BRI were significant predictors of MASLD risk even when fully adjusted, with Hazard Ratios (HR) of 1.80 (95% CI: 1.52-2.12) and 2.33 (95% CI: 1.96-2.76), respectively. In the joint analysis, the group with both high HOMA-IR and high obesity-related body shape index (BRI) showed a 3.58-fold (95% CI: 2.84-4.51) increased risk compared to the reference group. Notably, no significant additive or multiplicative interactions were found, confirming that these two factors serve as independent and distinct predictive markers.
conclusionsCombining HOMA-IR with body shape-related obesity markers like BRI provides a more robust prediction of MASLD risk than individual indices. These findings suggest that integrated monitoring of metabolic and morphological profiles is essential for the early identification of high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.